JP2023552919A5 - - Google Patents
Info
- Publication number
- JP2023552919A5 JP2023552919A5 JP2023552151A JP2023552151A JP2023552919A5 JP 2023552919 A5 JP2023552919 A5 JP 2023552919A5 JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552151 A JP2023552151 A JP 2023552151A JP 2023552919 A5 JP2023552919 A5 JP 2023552919A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- ryk
- item
- antibody derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112616P | 2020-11-11 | 2020-11-11 | |
| US63/112,616 | 2020-11-11 | ||
| PCT/US2021/058491 WO2022103705A1 (en) | 2020-11-11 | 2021-11-08 | Antibody variants against wnt receptor ryk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552919A JP2023552919A (ja) | 2023-12-19 |
| JP2023552919A5 true JP2023552919A5 (https=) | 2024-10-24 |
Family
ID=81601681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552151A Pending JP2023552919A (ja) | 2020-11-11 | 2021-11-08 | Ｗｎｔ受容体ｒｙｋに対する抗体バリアント |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230416375A1 (https=) |
| EP (1) | EP4244259A4 (https=) |
| JP (1) | JP2023552919A (https=) |
| KR (1) | KR20230107628A (https=) |
| CN (1) | CN117295767A (https=) |
| AU (1) | AU2021380681A1 (https=) |
| CA (1) | CA3201419A1 (https=) |
| TW (1) | TW202233683A (https=) |
| WO (1) | WO2022103705A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172733A1 (en) | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100522242C (zh) * | 2001-02-19 | 2009-08-05 | 默克专利有限公司 | 具有降低的免疫原性的人工蛋白质 |
| US8236307B2 (en) * | 2007-08-03 | 2012-08-07 | Genentech, Inc. | Humanized anti-FGF19 antagonists and methods using same |
| EP3533803B1 (en) * | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| EP3828205A1 (en) * | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| US20130309223A1 (en) * | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| US9862776B2 (en) * | 2013-04-03 | 2018-01-09 | Peter Maccallum Cancer Institute | Antibodies against human RYK and uses therefor |
| MA41480A (fr) * | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | Anticorps qui se lient au ccr6 et leurs utilisations |
| DK3303396T5 (da) * | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| WO2017172733A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
| AU2018224094B2 (en) * | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201707561D0 (en) * | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
-
2021
- 2021-11-08 WO PCT/US2021/058491 patent/WO2022103705A1/en not_active Ceased
- 2021-11-08 AU AU2021380681A patent/AU2021380681A1/en active Pending
- 2021-11-08 JP JP2023552151A patent/JP2023552919A/ja active Pending
- 2021-11-08 CA CA3201419A patent/CA3201419A1/en active Pending
- 2021-11-08 CN CN202180089301.4A patent/CN117295767A/zh active Pending
- 2021-11-08 KR KR1020237019599A patent/KR20230107628A/ko active Pending
- 2021-11-08 EP EP21892641.8A patent/EP4244259A4/en active Pending
- 2021-11-08 US US18/035,407 patent/US20230416375A1/en active Pending
- 2021-11-11 TW TW110141972A patent/TW202233683A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102291971B1 (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| KR102366682B1 (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| TWI432451B (zh) | 新穎之抗ｉｇｆ-ｉｒ抗體及其用途 | |
| KR102308493B1 (ko) | 신경퇴행성 장애의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| JP2022023182A (ja) | 脱髄障害の治療のための併用療法および使用 | |
| JP6955721B2 (ja) | ＲＧＭａ結合タンパク質及びその使用 | |
| FR2888850A1 (fr) | Nouveaux anticorps anti-igf-ir et leurs applications | |
| JP7742433B2 (ja) | 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法 | |
| JP2020522512A5 (https=) | ||
| JP2023159355A (ja) | Ｅｌｔｄ１に対するモノクローナル抗体及びその使用 | |
| Kanno et al. | Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis | |
| JP2023552919A5 (https=) | ||
| CA3158364A1 (en) | Anti-alpha-synuclein monoclonal antibodies, and methods using same | |
| CN111789954B (zh) | 延缓衰老的方法和药物 | |
| EP4082574A1 (en) | Agent for preventing or treating acute-phase neuromyelitis optica | |
| US20240043562A1 (en) | Musk activation | |
| RU2822199C2 (ru) | Способ предупреждения или лечения периферической нейропатии или боли, сопровождающей заболевание, при котором выявлена периферическая нейропатия или нарушение астроцитов | |
| WO2025254163A1 (ja) | 抗ｃａｄｍ１抗体およびその抗原結合断片 | |
| KR20260062948A (ko) | Ctla4/tigit 결합 단백질 및 이의 의학적 용도 | |
| HK40118760A (zh) | 特异性结合api5蛋白的抗体 | |
| CN118946581A (zh) | 特异性结合api5蛋白的抗体 | |
| KR20240063995A (ko) | 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링 | |
| CN120112560A (zh) | 用于治疗癌症的抗bssl抗体 | |
| CN110291110A (zh) | 特异性结合pauf蛋白的抗体及其用途 |